Australia markets closed

Gyre Therapeutics Inc. (L9S.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
12.00-0.30 (-2.44%)
As of 08:08AM CEST. Market open.
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
Total revenue
115,691
113,450
102,290
89,587
Cost of revenue
4,490
4,636
4,793
4,021
Gross profit
111,201
108,814
97,497
85,566
Operating expenses
Research development
13,327
13,780
16,686
7,246
Selling general and administrative
77,254
75,821
71,608
48,332
Total operating expenses
90,581
89,601
88,294
55,433
Operating income or loss
20,620
19,213
9,203
30,134
Interest expense
-
-
43.3377
122.3702
Total other income/expenses net
-92,563
-97,222
-517
-788.6604
Income before tax
-70,755
-76,965
9,412
29,605
Income tax expense
9,007
8,515
5,098
6,168
Income from continuing operations
-79,762
-85,480
4,314
23,437
Net income
-87,645
-92,933
2,302
23,437
Net income available to common shareholders
-87,645
-92,933
2,302
23,437
Basic EPS
1.94
-1.41
0.03
0.31
Diluted EPS
1.94
-1.41
0.03
0.31
Basic average shares
76,584
65,832
76,584
76,584
Diluted average shares
76,584
65,832
76,584
76,584